Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Glass House Brands ( ($TSE:GLAS.A.U) ) has provided an update.
Glass House Brands has welcomed the Trump administration’s move to reschedule cannabis to Schedule III and to launch a Medicare pilot reimbursing CBD purchases, positioning the changes as a watershed moment for U.S. drug policy and medical cannabis acceptance. The company believes rescheduling will open export opportunities and accelerate growth in the domestic CBD market, and it aims to leverage its low-cost, high-quality cannabinoid production, existing CBD and low-THC strains, and a research partnership with the University of California Berkeley to become a major supplier to the newly created multibillion-dollar Medicare-backed CBD market, while expanding cultivation capacity with its legacy greenhouses fully planted and further acreage growth planned for early 2026.
The most recent analyst rating on ($TSE:GLAS.A.U) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Glass House Brands stock, see the TSE:GLAS.A.U Stock Forecast page.
More about Glass House Brands
Glass House Brands is a vertically integrated cannabis company focused on the California market, operating cultivation, manufacturing and a network of retail dispensaries. Its portfolio includes brands such as Glass House Farms, PLUS Products, Allswell and Mama Sue Wellness, with an emphasis on sustainably produced cannabis and cannabinoid-based wellness products across multiple consumer segments.
See more insights into GLAS.A.U stock on TipRanks’ Stock Analysis page.